AMED3001 Cancer
The Complete Exam Bible · S1 2027AMED3001 Overview
- University of Sydney
- S1 2027
- 11 chapters
- Biology
AMED3001 Cancer is the University of Sydney's third-year, 6-credit-point unit in the School of Medical Sciences, co-taught at Westmead with the advanced stream AMED3901, and it is built around three modules: Cancer Facts & Diagnosis, Carcinogenesis, and Cancer Treatment.
- Assessed by Final Exam 50% · Mid-Semester Quiz 20% · Module 1 Practical Report 10% · Module 2 Practical Assignment 10% + 3 more
- Key terms Neoplasm (benign vs malignant), Metastasis, Oncogene, Tumour-suppressor gene (TSG)
- How to prepare Treat AMED3001 as three connected stories — what cancer is, why it happens, and how it is treated…
- Most asked Where can I find past exam papers/practice for AMED3001?
How AMED3001 is assessed
| Component | Weight | Format |
|---|---|---|
| Final Exam | 50% | USyd S1 exam period; MCQ + short-answer, marks vary per question; lectures + workshops + data-interpretation (heatmaps, gene-sequence annotation) examinable |
| Mid-Semester Quiz | 20% | ~Week 9 |
| Module 1 Practical Report | 10% | ~Week 4-5 (cancer pathology practical) |
| Module 2 Practical Assignment | 10% | ~Week 8 |
| Module 3 Practical Report | 6% | ~Week 13 (comet-assay / DNA-damage practical) |
| Student Pitch | 4% | ~Week 12 (precision-medicine pitch) |
| Module 1 Quiz | 0% (formative) | ~Week 4 |
What AMED3001 covers
AMED3001 Cancer is taught across three modules — Cancer Facts & Diagnosis, Carcinogenesis, and Cancer Treatment — and this eleven-chapter map follows that schedule from the hallmarks of cancer through to precision medicine.
The University of Sydney assesses AMED3001 through continuous coursework (practical reports, a Module-2 poster assignment, a mid-semester quiz and a 3-minute pitch) plus a comprehensive final exam worth 50% (confirm on Canvas), whose MCQ and short-answer questions span every lecture and workshop and, the coordinator confirms, data-interpretation skills — reading gene-expression heatmaps and annotating gene sequences.
Use it to see how each week's mechanism builds toward that final.
Cancer Facts, Impact & the Hallmarks of Cancer
What cancer is · incidence/impact · the cancer journey · the hallmarks framework (Module 1, Week 1)Week 1 of Module 1 sets up the whole unit.
- What cancer is: uncontrolled proliferation / dysregulated homeostasis; cancer arises from a single cell with critical DNA damage
- Benign vs malignant: expansile vs infiltrative growth; malignant spreads via blood and lymph
- Cancer nomenclature: carcinoma (epithelial), adenocarcinoma (glandular), sarcoma (mesenchymal), leukaemia/lymphoma/myeloma
- Incidence (new cases in a period) vs prevalence (total living with disease at a point in time)
- Survival metrics: overall survival (OS), disease-free survival (DFS), progression-free survival (PFS)
- The cancer journey and general warning signs; the global burden and modifiable risk factors
Tumour Structure, the Microenvironment & Metastasis
Tumour architecture · the tumour microenvironment · angiogenesis · the invasion-metastasis cascade (Module 1, Week 2)Week 2 turns from the cancer cell to its ecosystem and its spread.
- Tumour microenvironment (TME): cancer cells + non-cancer cells + extracellular matrix + signalling molecules
- Cancer-associated fibroblasts (CAFs) and tumour-associated macrophages (TAMs: M1-like inflammatory vs M2-like tumour-supporting)
- Cancer stem cells: quiescent/slow-cycling, therapy-resistant, can rebuild a whole tumour
- Tumour angiogenesis and abnormal leaky vasculature → hypoxia, acidity, high interstitial fluid pressure
- Hot vs cold tumours: CD8+ T-cell infiltration and immune-checkpoint activation
- The invasion-metastasis cascade in order: local invasion → intravasation → survival in circulation → extravasation → colonisation
Histopathology, Grading, Staging & Screening
Tissue diagnosis · grade vs stage (TNM) · biomarkers · population screening (Module 1, Weeks 3-4)Weeks 3-4 cover how cancer is diagnosed and detected.
- Tissue diagnosis: biopsy, the Haematoxylin & Eosin (H&E) stain, and reading morphology (cytology + tissue architecture)
- Cancer cell and nuclear features: pleomorphism, hyperchromasia, high nuclear:cytoplasmic ratio, increased and abnormal mitoses
- Carcinoma in situ vs invasive cancer: breach of the basement membrane
- GRADE = intrinsic aggressiveness (differentiation, growth pattern, mitotic count); Nottingham system for breast cancer
- STAGE = amount and spread, scored by TNM (Tumour, Nodes, Metastasis) → Stage I-IV
- Prognostic (e.g. Ki67) vs predictive (e.g. ER) biomarkers; IHC; tumour markers CEA, AFP, CA125, CA19-9
Cancer Aetiology & Carcinogens
Chemical/physical/biological carcinogens · mutagenesis · initiation-promotion-progression (Module 2, Week 5)Week 5 opens Module 2 with what causes cancer.
- Aetiology and the causation split: hereditary 5-10%, familial 10-20%, sporadic 70-80%; ~80-90% of cancers driven by somatic mutation
- Hereditary cancer syndromes: BRCA1/2 (breast/ovarian), Lynch (mismatch-repair genes), FAP (APC), Li-Fraumeni (TP53)
- Physical carcinogens: ionizing radiation → single- and double-strand breaks; UV → pyrimidine dimers (CPDs, 6-4 photoproducts)
- Chemical carcinogens: polycyclic aromatic hydrocarbons, alkylating agents, aflatoxin (activated by liver CYP450), asbestos → mesothelioma
- IARC classification: Group 1 (carcinogenic), 2A (probable), 2B (possible), 3 (not classifiable)
- Biological carcinogens: viruses (HPV, HBV/HCV, EBV), bacteria (H. pylori), flukes (Opisthorchis, Schistosoma)
Gene Mutations, Oncogenes & Tumour-Suppressor Genes
Proto-oncogenes → oncogenes · tumour-suppressor genes · the two-hit hypothesis · p53 & Rb (Module 2, Week 6)Week 6 is the genetic core of the unit.
- Point mutations: synonymous/silent, missense (amino-acid substitution), nonsense (premature stop → truncated protein)
- Frameshift indels and splicing mutations (exon skipping, intron retention); variant of unknown significance (VUS)
- Structural/copy-number variants: amplification (HER2 in breast, EGFR in colon), deletion, translocation
- BCR-ABL1: t(9;22) Philadelphia chromosome → constitutively active tyrosine kinase → inhibited by imatinib
- Oncogenes: gain-of-function, a single activating hit; RAS, MYC, EGFR, HER2, BRAF
- Tumour-suppressor genes: loss-of-function, both alleles hit; p53, Rb, APC, BRCA1/2
Cancer Gene Activation, Epigenetics & Driver Pathways
Viral · epigenetic · ncRNA regulation · critical driver genes & pathways (Module 2, Week 7)Week 7 explains how cancer genes are switched on and off beyond simple mutation, and maps the driver pathways that recur across cancers.
- Viral oncogenesis: viral genome integration; HPV E6 → degrades p53, E7 → degrades pRb; insertional mutagenesis driving c-myc
- Epigenetics: heritable, reversible changes in gene activity without altering the DNA sequence
- DNA methyltransferases (writers) add methyl to cytosine → 5-methylcytosine at promoter CpG islands → gene silencing
- Promoter hypermethylation silences tumour suppressors (CDKN2A/p16, MLH1, BRCA1, APC)
- MLH1 silencing → mismatch-repair deficiency → microsatellite instability (MSI), which responds well to immunotherapy
- Histone modification (methylation, deacetylation) and non-coding RNA (lncRNA, miRNA; EPIC1-MYC)
Cancer Evolution & Molecular Technologies
Clonal evolution · intratumour heterogeneity · sequencing & omics technologies (Module 2, Week 8)Week 8 frames cancer as an evolving system and introduces the technologies used to study it — the basis for the exam's data-interpretation questions.
- Multistep carcinogenesis; transformation needs cooperating mutations (myc + ras together, not alone)
- Colon adenoma-to-carcinoma sequence: APC loss → KRAS activation → SMAD4/other TSG loss → p53 loss
- Tumour heterogeneity theories: Darwinian clonal expansion vs cancer-stem-cell; drug-resistant clones evolve under therapy
- Sequencing: Sanger vs next-generation; whole-genome (>30×) vs whole-exome (>50-100×) vs targeted panel (>500×)
- RNA-seq for differential expression → heatmaps (Row Z-score, red up/blue down) and volcano plots
- Single-cell RNA-seq and spatial profiling; clustering with t-SNE/UMAP
Conventional Therapy & Therapy-Induced DNA Damage
Chemotherapy · radiotherapy · the DNA-damage response · the comet assay (Module 3, Week 10)Week 10 opens Module 3 with conventional cancer treatment.
- Three conventional modalities: surgery (localised, early-stage), radiotherapy, chemotherapy
- Radiotherapy: ionizing radiation → DNA double-strand breaks → cell death; fast-dividing cells most sensitive
- Chemotherapy classes: alkylating agents (DNA damage), antimetabolites (block DNA synthesis), taxanes (mitotic-spindle disruption)
- Cell-cycle checkpoints (G1/S, G2/M, M) and the DNA-damage response
- Drug resistance: efflux pumps (P-glycoprotein), DNA-repair upregulation, tumour heterogeneity
- Cancer stem cells escape chemo by G0 quiescence → therapy-induced damage can promote survival → relapse
Targeted Therapy, Cell Therapy & Immunotherapy
Targeted small molecules & antibodies · CAR-T · immune-checkpoint inhibitors · gene/RNA therapy (Module 3, Week 11)Week 11 covers modern cancer therapeutics: targeted small molecules and monoclonal antibodies against the driver pathways, cellular therapy (CAR-T), immune-checkpoint inhibitors, and gene and RNA therapy.
- Conventional vs targeted therapy: specificity, side effects, cost and availability
- Targeted small molecules and monoclonal antibodies against driver pathways (trastuzumab; EGFR/BRAF inhibitors)
- Antibody-drug conjugates (T-DM1, T-DXd): antibody plus an internalised cytotoxic payload
- Tumour immune evasion: checkpoint activation (PD-1/PD-L1, CTLA-4), MDSCs, Tregs, exhausted T cells
- Immune-checkpoint inhibitors (anti-PD-1, e.g. pembrolizumab) restore cytotoxic T-cell activity
- CAR-T cell therapy: T cells engineered with a chimeric antigen receptor (e.g. Kymriah) for B-cell malignancies
Precision Medicine & Key Technologies
Biomarkers & companion diagnostics · matching therapy to the tumour · key enabling technologies (Module 3, Week 12)Week 12 closes Module 3 with precision (personalised) medicine — matching a treatment to a tumour's molecular profile to overcome heterogeneity and resistance — and the enabling technologies (genomics, nanotechnology, AI).
- One-size-fits-all vs precision medicine; profiling each tumour to address heterogeneity and acquired resistance
- Biomarkers and companion diagnostics; matching a therapy to a tumour's molecular profile
- Genomic tumour testing (acquired mutations, tumour only, not heritable) vs hereditary germline testing (inherited, every cell, blood/saliva)
- BRCA1/PARP synthetic lethality; breast-cancer subtypes (~6:2:2 ER+ : HER2+ : triple-negative)
- Liquid biopsy for monitoring (ctDNA); ~5-10% of breast cancers are inherited
- Key enabling technologies: genomics, nanotechnology (lipid nanoparticles) and AI
Data Interpretation in Cancer Biology
Reading gene-expression heatmaps · volcano plots · gene-sequence annotation (exam skill)This chapter gathers the data-interpretation skill the coordinator explicitly confirms is examinable across all modules: reading gene-expression heatmaps, volcano plots and single-cell clusters, and annotating gene sequences.
- Why data interpretation is examinable (coordinator: heatmaps for gene expression, annotations for gene sequences)
- Reading a gene-expression heatmap: rows = genes, columns = samples, colour = Row Z-score (red = up, blue = down), clustering groups similar profiles
- Volcano plot: log2 fold-change on the x-axis, −log10 p-value on the y-axis; significant hits sit top-left/top-right (±2-fold, q < 0.05)
- Single-cell UMAP/t-SNE clusters: each cluster a cell type (e.g. EPCAM-high = epithelial/tumour)
- Gene-sequence annotation: promoter, exons and introns; sense vs anti-sense strand
- Variant interpretation: ClinVar (pathogenic vs benign), COSMIC (reported somatic), cross-species conservation (conserved → likely damaging)
The unit works from what cancer is — the hallmarks of cancer, tumour structure and metastasis, histopathology, grading and staging — through why it happens — carcinogens, oncogenes and tumour-suppressor genes, epigenetics, driver pathways and clonal evolution — to how it is treated — conventional chemo- and radiotherapy, targeted and cell therapy, immunotherapy and precision medicine.
It is a mechanism-and-reasoning subject: the marks reward naming the right pathway, stating a mechanism in the correct direction, and interpreting real data.
AMED3001 is assessed through Canvas as continuous coursework — a Module 1 practical report (10%), a Module 2 practical assignment (10%), a mid-semester quiz (20%), a 3-minute student pitch (4%) and a Module 3 practical report (6%) — capped by a comprehensive final examination worth 50% (the weight is set in the Canvas unit outline, not the public handbook — confirm on Canvas).
Per the unit coordinator the final is MCQ plus short-answer with marks varying per question, and everything from lectures and workshops is examinable, including data-interpretation skills — reading gene-expression heatmaps and annotating gene sequences. That structure rewards steady work across the semester and through STUVAC, and the AMED3001 result feeds the Weighted Average Mark (WAM) that later units build on.
(AMED3901 Cancer Advanced shares the same 50% exam but replaces the smaller AMED3001 tasks with a 20% case-study presentation.)
Worked example · free
Synthetic lethality: why a PARP inhibitor works in BRCA1-mutant triple-negative breast cancer
- +1BRCA1 is a tumour-suppressor gene essential for repairing DNA double-strand breaks by homologous recombination (HR), working with BRCA2, PALB2 and RAD51.
- +1In the tumour, BRCA1 function is lost, so the cancer cells are HR-deficient and cannot accurately repair double-strand breaks; normal cells still carry a working BRCA1 allele and remain HR-competent.
- +1PARP1 normally repairs single-strand breaks (base-excision repair). A PARP inhibitor leaves single-strand breaks unrepaired, and at the replication fork these collapse into double-strand breaks.
- +1Synthetic lethality: in the HR-deficient tumour cell those double-strand breaks cannot be repaired → genomic catastrophe → apoptosis, whereas the HR-competent normal cell repairs them and survives — two individually survivable defects are lethal only together.
- +1Personalised rationale: match therapy to the molecular profile — surgery to remove the primary, then chemotherapy plus a PARP inhibitor exploiting the BRCA1 defect, with BRCA status confirmed by hereditary (germline) genetic testing.
Key terms
- Neoplasm (benign vs malignant)
- An abnormal mass of tissue arising when cells proliferate more than they should or fail to die. Benign = does not invade or spread; malignant (cancer) = invades local tissue and can spread via blood and lymph.
- Metastasis
- The spread of cancer cells from the primary tumour to a distant site to form secondary tumours. More than 90% of cancer deaths are due to metastasis.
- Oncogene
- A gain-of-function mutant of a normal proto-oncogene that drives proliferation; a single activating hit is sufficient. Examples: RAS, MYC, EGFR, HER2, BRAF.
- Tumour-suppressor gene (TSG)
- A gene whose normal product restrains division or triggers repair/death; cancer arises through loss of function, and both alleles must be inactivated (the two-hit hypothesis). Examples: p53, Rb, APC, BRCA1/2.
- Grade vs Stage
- Grade = intrinsic aggressiveness read microscopically (differentiation, growth pattern, mitotic count). Stage = the amount and spread of cancer in the body, scored by the TNM system (Tumour, Nodes, Metastasis).
- Hallmarks of cancer
- The organising framework (Hanahan & Weinberg) of the capabilities a tumour acquires — sustained proliferation, evading growth suppressors, resisting death, replicative immortality, angiogenesis and invasion/metastasis, plus deregulated metabolism and immune evasion, enabled by genome instability and tumour-promoting inflammation.
AMED3001 FAQ
Is AMED3001 hard?
It is broad rather than mathematically hard — there are no calculations, but the unit runs from cell biology and histopathology through molecular genetics to therapeutics, so the challenge is keeping a large web of mechanisms and their directions straight (which gene is a tumour suppressor, which pathway a driver activates, which therapy hits which target).
Students who revise the recurring mechanisms weekly rather than cramming through STUVAC, and who practise the data-interpretation skills the coordinator flags, tend to find it manageable. The mid-semester quiz (20%) and continuous practicals mean marks accumulate all semester, and the result feeds your Weighted Average Mark (WAM).
Can AI help me with AMED3001?
Yes — Sia is an AI tutor trained on how AMED3001 is actually taught and assessed. It explains a mechanism step by step — how HPV E6/E7 disable p53 and pRb, why a PARP inhibitor is synthetically lethal in a BRCA-mutant cell, or how to read a gene-expression heatmap — and checks your reasoning as you work. It does not do graded assessment for you, and University of Sydney academic-integrity rules apply.
Use it to understand the method and rehearse, then confirm assessment details on Canvas and the unit outline.
Where can I find past exam papers/practice for AMED3001?
Start on Canvas, where the unit posts its official material, and search the University of Sydney Library past-exam-paper collection; your lecture and workshop concepts plus the practical questions are the closest guide to the final's style, since the coordinator says the papers you analysed are not examined in detail (only the underlying concepts and the data-interpretation skill).
This guide also includes a re-authored practice exam that mirrors the final's MCQ-plus-short-answer shape with fresh scenarios, and you can ask Sia to build extra practice in the same style and explain each step. Treat any third-party ‘model answers’ with caution.
Does AMED3001 have a hurdle, and how is it assessed?
No hurdle is stated in the available unit materials — but absence of a stated hurdle is not the same as a confirmed ‘no hurdle’, so check the current rules on Canvas and the unit outline; do not assume either way.
Assessment is continuous: a Module 1 practical report (10%), a Module 2 practical assignment (10%), a mid-semester quiz (20%), a 3-minute pitch (4%) and a Module 3 practical report (6%), plus the final exam worth 50% (the weight is set in the Canvas outline, not the public handbook — confirm on Canvas). Grade bands are the standard USyd HD/D/CR/P.
What is examined in the AMED3001 final?
Per the unit coordinator the final is MCQ plus short-answer (up to a short paragraph) with marks varying per question, and everything from the lectures and workshops is examinable. Crucially, data-interpretation is examinable — reading gene-expression heatmaps and annotating gene sequences — so practise those alongside the mechanisms.
The research papers you analysed and the databases you explored are not examined in detail, only the underlying lecture concepts. Exam duration, open-versus-closed-book status and the number of questions are not published in the unit materials — confirm them on Canvas and the exam timetable.
Questions students ask in each AMED3001 chapter
- Is a benign tumour cancer?
- No. A benign neoplasm can grow large but has regular borders, stays in its primary location and does not invade surrounding tissue or metastasise. Cancer means a malignant neoplasm — one that can invade local tissue and spread via blood and lymph. The distinction is a common definition MCQ. Chapter 01 · Cancer Facts, Impact & the Hallmarks of Cancer
- Why is metastasis, not the primary tumour, the main cause of cancer death?
- More than 90% of cancer deaths are due to metastases rather than the primary tumour, because disseminated disease is systemic and hard to remove surgically. That is why the invasion-metastasis cascade and EMT are heavily examined. Chapter 02 · Tumour Structure, the Microenvironment & Metastasis
- What is the difference between cancer grade and cancer stage?
- Grade describes how aggressive the cancer cells look under the microscope (differentiation, growth pattern, mitotic count); stage describes how much cancer there is and how far it has spread (TNM). Two tumours can share a stage but differ in grade — this contrast is one of the most reliably examined short answers. Chapter 03 · Histopathology, Grading, Staging & Screening
- What is the hereditary/familial/sporadic split of cancer causation?
- Roughly 5-10% hereditary (a known inherited germline mutation), 10-20% familial (runs in families with an unknown genetic cause and gene-environment interaction) and 70-80% sporadic (chance somatic events). Knowing these proportions with one example each is a common short answer. Chapter 04 · Cancer Aetiology & Carcinogens
- How many mutations activate an oncogene versus inactivate a tumour-suppressor gene?
- An oncogene needs only a single activating (gain-of-function) hit, because the effect is dominant. A tumour-suppressor gene needs both alleles inactivated (the two-hit hypothesis) before its restraining function is lost. Mixing these up is the most common genetics error in the exam. Chapter 05 · Gene Mutations, Oncogenes & Tumour-Suppressor Genes
- How can a tumour-suppressor gene be inactivated without a mutation?
- Through epigenetic silencing: dense promoter CpG-island hypermethylation closes the chromatin and stops the gene being transcribed, so its protein is lost even though the DNA sequence is intact. CDKN2A, MLH1 and BRCA1 are silenced this way in various cancers. Chapter 06 · Cancer Gene Activation, Epigenetics & Driver Pathways
- Why can one mutation rarely cause cancer on its own?
- Transformation usually needs cooperating mutations: in classic experiments myc or ras alone did not make a tumour, but myc plus ras did. Cancer is multistep, accumulating oncogene activations and tumour-suppressor losses — as the colon adenoma-to-carcinoma sequence shows. Chapter 07 · Cancer Evolution & Molecular Technologies
- How do radiotherapy and chemotherapy actually kill cancer cells?
- Radiotherapy uses ionizing radiation to cause DNA double-strand breaks; chemotherapy classes act differently — alkylating agents damage DNA directly, antimetabolites block DNA synthesis, and taxanes disrupt the mitotic spindle. All target fast-dividing cells, which is why normal fast-dividing tissues also suffer side effects. Chapter 08 · Conventional Therapy & Therapy-Induced DNA Damage
- How is targeted therapy different from conventional chemotherapy?
- Conventional chemotherapy is non-specific, hitting all fast-dividing cells (cancer and healthy) with high side effects but low cost; targeted therapy acts on a specific molecule in the cancer, giving fewer side effects and the prospect of longer remission, but at higher cost and limited availability. Chapter 09 · Targeted Therapy, Cell Therapy & Immunotherapy
- What is the difference between genomic tumour testing and hereditary genetic testing?
- Genomic tumour testing analyses acquired (somatic) mutations in the tumour to guide treatment, and these are not heritable; hereditary testing analyses inherited (germline) mutations present in every cell (from blood or saliva) that can be passed on, to identify at-risk individuals. This two-axis contrast is a reliable short answer. Chapter 10 · Precision Medicine & Key Technologies
- Do I really need to read heatmaps and volcano plots for the AMED3001 exam?
- Yes — the unit coordinator explicitly states that data-interpretation is examinable, naming heatmaps for gene-expression analyses and annotations for gene sequences. The papers you analysed are not examined in detail, but the generic skill of reading these figures is, so practise it directly. Chapter 11 · Data Interpretation in Cancer Biology
How to study for the exam
Treat AMED3001 as three connected stories — what cancer is, why it happens, and how it is treated — and revise the recurring mechanisms weekly rather than banking on a STUVAC cram, because the mid-semester quiz (20%) and the practicals spread the marks across the whole semester.
For each topic, be able to state the mechanism in the correct direction (which gene is lost versus activated, which pathway a driver switches on, whether a therapy is an agonist or an inhibitor) and give one worked example — a driver mutation, a therapy mechanism, a screening decision.
Because the coordinator confirms data-interpretation is examinable, practise reading gene-expression heatmaps (rows, columns, red/blue Row Z-score, clustering), volcano plots and gene-sequence annotations until they are automatic. Keep the whole unit warm for the comprehensive 50% final rather than deep-diving one module.
When a mechanism won't click, ask Sia to re-explain that single step a different way and to set you a fresh practice question in the same style — it teaches the method and checks your reasoning, and it never substitutes for your own graded work. Confirm the exam date, room and open/closed-book status on Canvas and the University of Sydney exam timetable.
Your AI Biology tutor for AMED3001
Stuck on a hard AMED3001 question? Sia is AskSia’s AI Biology tutor — ask any AMED3001 Cancer question and get a clear, step-by-step explanation grounded in how the course is actually taught and assessed. Read this whole study guide free, then take your hardest questions to Sia.
